CHINA PHARMA HOLDINGS, INC.
About CHINA PHARMA HOLDINGS, INC.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $4.1M
- Net income
- -$3.2M
- Total assets
- $31.0M
- Market cap
- $29.0M
- Gross margin
- -3.2%
- Operating margin
- -78.2%
- Net margin
- -76.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.1M
- Cost of revenue
- $4.3M
- Gross profit
- -$131.9K
- Operating expenses
- $3.1M
- Operating income
- -$3.2M
- Net income
- -$3.2M
- EPS (basic)
- $-0.74
- EPS (diluted)
- $-0.74
Balance sheet
- Total assets
- $31.0M
- Current assets
- $2.3M
- Total liabilities
- $8.3M
- Current liabilities
- $7.4M
- Shareholders’ equity
- $22.7M
Cash flow
- Operating cash flow
- $148.3K
- Investing cash flow
- -$137.3K
- Financing cash flow
- -$294.0K
- Net cash flow
- -$281.8K
Statements via Polygon.io (SEC filings)
- Market cap
- $29.0M
- EPS (diluted)
- $-0.74
- Shares outstanding
- 40.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 14, 2002
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $3.2M in FY2025.
- Revenue declined 57% from FY2021 to FY2025.
- Gross margin of -3.2%, net margin -76.9%.
- Trading 70% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CHINA PHARMA HOLDINGS, INC..
Write a review
News about CHINA PHARMA HOLDINGS, INC.
News & sentiment via Polygon.io
